Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Svedbom

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Patient Preference and Adherence|February 2, 2017
Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment lineAxel Svedbom, Johan Dalén, Christopher M Black, et al.
Rheumatology International|October 5, 2017
Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitorsJohan Dalén, Axel Svedbom, Christopher M Black, et al.
Patient Preference and Adherence|April 25, 2017
Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritisAxel Svedbom, Chiara Storck, Sumesh Kachroo, et al.
The Journal of Dermatological Treatment|September 4, 2024
Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register studyAxel Svedbom, Christina Wennerström, Fredrik Hjelm, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 7, 2018
Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in SpainErin Johansson, Mercedes Nuñez, Axel Svedbom, et al.
Advances in Therapy|July 11, 2020
Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective StudyJohan Dalén, Karin Luttropp, Axel Svedbom, et al.
Advances in Therapy|September 4, 2021
Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective StudyJohan Dalén, Amy Puenpatom, Karin Luttropp, et al.
Advances in Therapy|August 20, 2023
Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by IndicationJohan Dalén, Axel Svedbom, Emma Hernlund, et al.
Journal of Medical Economics|June 7, 2018
Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UKErin Colleen Johansson, Susanne Hartz, Sandeep Himatlal Kiri, et al.
Acta Dermato-Venereologica|August 7, 2025
Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish CohortPontus O Jonsson, Mahsa Tayefi, Axel Svedbom, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Patient Preference and Adherence|February 2, 2017
Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment lineAxel Svedbom, Johan Dalén, Christopher M Black, et al.
Rheumatology International|October 5, 2017
Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitorsJohan Dalén, Axel Svedbom, Christopher M Black, et al.
Patient Preference and Adherence|April 25, 2017
Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritisAxel Svedbom, Chiara Storck, Sumesh Kachroo, et al.
The Journal of Dermatological Treatment|September 4, 2024
Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register studyAxel Svedbom, Christina Wennerström, Fredrik Hjelm, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 7, 2018
Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in SpainErin Johansson, Mercedes Nuñez, Axel Svedbom, et al.
Advances in Therapy|July 11, 2020
Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective StudyJohan Dalén, Karin Luttropp, Axel Svedbom, et al.
Advances in Therapy|September 4, 2021
Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective StudyJohan Dalén, Amy Puenpatom, Karin Luttropp, et al.
Advances in Therapy|August 20, 2023
Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by IndicationJohan Dalén, Axel Svedbom, Emma Hernlund, et al.
Journal of Medical Economics|June 7, 2018
Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UKErin Colleen Johansson, Susanne Hartz, Sandeep Himatlal Kiri, et al.
Acta Dermato-Venereologica|August 7, 2025
Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish CohortPontus O Jonsson, Mahsa Tayefi, Axel Svedbom, et al.
Pageof 5